Om Medipharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -33.93%
(FY 2022)
- Profit -250.63%
(FY 2022)
- Ebitda -15.29%
(FY 2022)
- Net Worth -5.39%
(FY 2022)
- Total Assets -1.76%
(FY 2022)
About Om Medipharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hem Tiwari, Vipin Tiwari, and Pawan Tiwari serve as directors at the Company.
- CIN/LLPIN
U24232RJ2010PTC032152
- Company No.
032152
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2010
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Om Medipharmaceuticals Private Limited offer?
Om Medipharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Herbal Platelet Capsule & Tablet, Cancer Herbal Medicine, Ayurvedic Pain Relief Oil, Ayurvedic Digestive Medicine, Digestive Herbal Capsule & Tablet, Asthma Herbal Capsule & Tablet.
Who are the key members and board of directors at Om Medipharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hem Tiwari  | Director | 01-Apr-2013 | Current |
| Vipin Tiwari | Director | 19-Jun-2010 | Current |
| Pawan Tiwari | Director | 19-Jun-2010 | Current |
Financial Performance and Corporate Structure Insights of Om Medipharmaceuticals.
Om Medipharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 33.93% decrease. The company also saw a substantial fall in profitability, with a 250.63% decrease in profit. The company's net worth dipped by a decrease of 5.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Om Medipharmaceuticals?
In 2019, Om Medipharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dr. N.L. Tiwari Pharmaceuticals Private Limited
Active
19 years 4 months Vipin Tiwari and Pawan Tiwari are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Om Medipharmaceuticals?
Unlock and access historical data on people associated with Om Medipharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Om Medipharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Om Medipharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
